{"paper_id":"e12168f8-9adb-4b99-957c-d2c72ab39ae5","body_text":"News\nEndometriosis: NICE approves new treatment option\nBMJ 2025; 389 doi: https://doi.org/10.1136/bmj.r883 (Published 01 May 2025) Cite this as: BMJ 2025;389:r883- Adrian O’Dowd\n- London\nA drug that was approved last year for uterine fibroids is now available for patients of reproductive age who have previously had medical or surgical treatment for endometriosis. In final draft guidance published on 1 May the UK National Institute for Health and Care Excellence (NICE) has recommended linzagolix (marketed as Yselty) with hormonal add-back therapy for symptoms of endometriosis in this group.1 …\nLog in\nLog in using your username and password\nLog in through your institution\nSubscribe from £184 *\nSubscribe and get access to all BMJ articles, and much more.\n* For online subscription\nAccess this article for 1 day for:\n£50 / $60/ €56 (excludes VAT)\nYou can download a PDF version for your personal record.","source_license":"CC0","license_restricted":false}